ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANAB is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The chart is technically constructive, but the stock is trading near fair value after a sharp run, analyst targets are mixed and recently cut by several firms, and the options market shows heavy bearish sentiment. I would not treat this as an immediate buy today; hold off unless you want to wait for a clearer pullback or stronger fundamental confirmation.
ANAB is in a short-term uptrend and remains above key moving averages, with SMA_5 > SMA_20 > SMA_200, which is bullish. MACD histogram is positive at 0.66, though it is contracting, suggesting momentum is still positive but fading. RSI_6 at 56.1 is neutral, so the stock is not overbought. Price at 66.79 is above the pivot of 62.713 and below resistance at 71.331, leaving some upside room but not a clear breakout yet. The near-term pattern estimate is weak over longer horizons, with projected weakness over the week and month despite slight next-day strength.
["Technical trend remains bullish with price above the major moving averages.", "Piper Sandler and Leerink maintain constructive ratings with upside price targets above the current share price.", "Piper Sandler views the post-spinoff structure as a cleaner royalty business that may better protect value.", "Barclays notes accelerating Jemperli cash flows and potential upside from GSK development programs.", "2025/Q4 revenue increased 151.08% YoY, showing strong top-line growth."]
["No news in the recent week, so there is no fresh catalyst driving the stock right now.", "Several analysts cut price targets recently, including UBS and Barclays, showing valuation reset pressure.", "Options market sentiment is strongly bearish based on put-heavy positioning.", "Net income and EPS fell sharply year over year in Q4, indicating earnings quality is not yet consistent.", "The stock has already run strongly over the past year, which reduces the attractiveness of buying immediately at current levels."]
In Q4 2025, ANAB reported revenue of $108.25M, up 151.08% YoY, which is a strong growth signal. However, net income dropped to $49.61M, down 327.75% YoY, and EPS fell to $1.79, down 348.61% YoY, suggesting that profitability was volatile despite strong revenue growth. Gross margin was 100%, which is excellent, but the latest quarter still shows that earnings momentum is not as clean as revenue growth.
Analyst sentiment is mixed but still moderately positive overall. Piper Sandler recently lowered its target to $93 from $95 and kept Overweight. Leerink raised its target to $85 from $66 and kept Outperform. UBS cut its target to $60 from $90 while keeping Buy, and Barclays cut to $63 from $79 while maintaining Overweight. The broad takeaway is that Wall Street sees upside from the royalty model and Jemperli cash flows, but recent target cuts show some caution after the spin-off and valuation reset.
